HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DL… Read more
HTG Molecular Diagnostics Inc. (HTGMQ) - Net Assets
Latest net assets as of March 2023: $474.50K USD
Based on the latest financial reports, HTG Molecular Diagnostics Inc. (HTGMQ) has net assets worth $474.50K USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.87 Million) and total liabilities ($10.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $474.50K |
| % of Total Assets | 4.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | -74.44% |
| 10-Year Change | N/A |
| Growth Volatility | 47.96 |
HTG Molecular Diagnostics Inc. - Net Assets Trend (2012–2022)
This chart illustrates how HTG Molecular Diagnostics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HTG Molecular Diagnostics Inc. (2012–2022)
The table below shows the annual net assets of HTG Molecular Diagnostics Inc. from 2012 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $5.39 Million | -48.16% |
| 2021-12-31 | $10.40 Million | -28.20% |
| 2020-12-31 | $14.48 Million | -39.57% |
| 2019-12-31 | $23.97 Million | +13.64% |
| 2018-12-31 | $21.09 Million | +789.39% |
| 2017-12-31 | $-3.06 Million | +45.30% |
| 2016-12-31 | $-5.59 Million | -133.11% |
| 2015-12-31 | $16.89 Million | +170.27% |
| 2014-12-31 | $-24.04 Million | -7.09% |
| 2013-12-31 | $-22.45 Million | -22.94% |
| 2012-12-31 | $-18.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HTG Molecular Diagnostics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18748663100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.21K | 0.04% |
| Other Comprehensive Income | $2.68K | 0.05% |
| Other Components | $235.31 Million | 4364.38% |
| Total Equity | $5.39 Million | 100.00% |
HTG Molecular Diagnostics Inc. Competitors by Market Cap
The table below lists competitors of HTG Molecular Diagnostics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACME Printing and Packaging PLC
CM:ACMEN0000
|
$221.01 |
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
$221.02 |
|
iExalt Inc
OTCGREY:IEXA
|
$222.05 |
|
Mendocino Brewing Company Inc
PINK:MENB
|
$222.28 |
|
NATURAL COOL - Dusseldorf Stock Exchang
DU:N7E
|
$220.56 |
|
Siddiqsons Tin Plate Ltd
KAR:STPL
|
$220.43 |
|
PT Trimitra Trans Persada Tbk
JK:BLOG
|
$220.42 |
|
Blackrock Energy and Resources Income Trust PLC
LSE:BERI
|
$220.27 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HTG Molecular Diagnostics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 10,399,824 to 5,391,697, a change of -5,008,127 (-48.2%).
- Net loss of 21,594,476 reduced equity.
- Share repurchases of 11 reduced equity.
- New share issuances of 1,188 increased equity.
- Other comprehensive income increased equity by 785.
- Other factors increased equity by 16,584,387.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.59 Million | -400.51% |
| Share Repurchases | $11.19 | -0.0% |
| Share Issuances | $1.19K | +0.02% |
| Other Comprehensive Income | $785.00 | +0.01% |
| Other Changes | $16.58 Million | +307.59% |
| Total Change | $- | -48.16% |
Book Value vs Market Value Analysis
This analysis compares HTG Molecular Diagnostics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-9859.27 | $0.00 | x |
| 2013-12-31 | $-555.70 | $0.00 | x |
| 2014-12-31 | $-595.10 | $0.00 | x |
| 2015-12-31 | $672.99 | $0.00 | x |
| 2016-12-31 | $-141.53 | $0.00 | x |
| 2017-12-31 | $-51.97 | $0.00 | x |
| 2018-12-31 | $137.94 | $0.00 | x |
| 2019-12-31 | $113.24 | $0.00 | x |
| 2020-12-31 | $37.56 | $0.00 | x |
| 2021-12-31 | $17.99 | $0.00 | x |
| 2022-12-31 | $6.06 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HTG Molecular Diagnostics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -400.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -339.20%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 3.30x
- Recent ROE (-400.51%) is below the historical average (-90.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -514.91% | 0.29x | 0.00x | $-10.95 Million |
| 2013 | 0.00% | -524.70% | 0.51x | 0.00x | $-9.52 Million |
| 2014 | 0.00% | -419.30% | 0.38x | 0.00x | $-11.55 Million |
| 2015 | -126.66% | -529.44% | 0.10x | 2.33x | $-23.09 Million |
| 2016 | 0.00% | -507.32% | 0.28x | 0.00x | $-25.48 Million |
| 2017 | 0.00% | -128.46% | 0.69x | 0.00x | $-18.65 Million |
| 2018 | -78.01% | -76.52% | 0.49x | 2.08x | $-18.56 Million |
| 2019 | -80.51% | -100.49% | 0.43x | 1.88x | $-21.69 Million |
| 2020 | -144.08% | -244.13% | 0.24x | 2.43x | $-22.32 Million |
| 2021 | -164.86% | -192.49% | 0.29x | 2.93x | $-18.19 Million |
| 2022 | -400.51% | -339.20% | 0.36x | 3.30x | $-22.13 Million |
Industry Comparison
This section compares HTG Molecular Diagnostics Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HTG Molecular Diagnostics Inc. (HTGMQ) | $474.50K | 0.00% | 21.90x | $221.00 |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |